Skip to main content
SpringerLink
Log in

Radiation dose to rectum in high-dose-rate brachytherapy with a single implant and two fractions for prostate cancer, and its prediction by prostate volume

  • Published:
Radiological Physics and Technology Aims and scope Submit manuscript

Abstract

We aimed to clarify the differences between the estimated rectal dose (ERD) and the first measured dose (FMD) and second measured dose (SMD) to the rectum during high-dose-rate (HDR) brachytherapy, and to predict FMD from the prostate volume (PV) or the rectal dose–volume parameters (RDVPs). ERD, FMD, and SMD were assessed with a rectal dosimeter during HDR brachytherapy of 18 Gy given in two fractions to 110 patients (48 hormone recipients, 62 hormone-naïve patients) with prostate cancer. The correlations between FMD and PV, and between FMD and RDVP (D 2ml–D 5ml) were investigated. ERD (mean ± SD) was 219 ± 44 cGy, FMD was 255 ± 52 cGy, and SMD was 298 ± 63 cGy, which differed significantly (p < 0.001). The correlation coefficients between ERD and FMD, and between FMD and SMD, were 0.82 and 0.78, respectively. SMD was equivalent to 118 ± 16 % FMD. The measured doses were significantly greater in the hormone recipients than in the hormone-naïve patients (p < 0.001). The increase in FMD correlated with the increases in PV and in RDVPs. The correlation coefficients between PV and FMD in all of the patients, in the hormone recipients, and in the hormone-naïve patients were 0.61, 0.64, and 0.64, respectively, whereas that between RDVPs and FMD was <0.53. In conclusion, the dose to the rectum increased with time and was correlated with the increases in PV and RDVPs. The correlation coefficient between FMD and PV was greater than that between FMD and RDVPs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Stromberg J, Martinez A, Gonzalez J, Edmundson G, Ohanian N, Vicini F, Hollander J, Gustafson G, Spencer W, Yan D, Brabbins D. Ultrasound-guided high dose rate conformal brachytherapy boost in prostate cancer: treatment description and preliminary results of a phase I/II clinical trial. Int J Radiat Oncol Biol Phys. 1995;33:161–71.

    Article  CAS  PubMed  Google Scholar 

  2. Martinez AA, Gustafson G, Gonzalez J, Armour E, Mitchell C, Edmundson G, Spencer W, Stromberg J, Huang R, Vinci F. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53:316–27.

    Article  PubMed  Google Scholar 

  3. Demanes JD, Martinez AA, Ghilezan M, Hill DR, Schour L, Brandt D, Gustafson G. High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2011;81:1286–92.

    Article  PubMed  Google Scholar 

  4. Rogers CL, Alder CS, Rogers LR, Hopkins SA, Platt ML, Childs LC, Crouch RH, Hansen RS, Hayes JK. High dose brachytherapy as monotherapy for intermediate risk prostate cancer. J Urol. 2012;187:109–16.

    Article  PubMed  Google Scholar 

  5. Morton G, Loblaw A, Cheung P, Szumacher E, Chahal M, Danjoux C, Chung HT, Deabreu A, Mamedov A, Zhang L, Viqneault E, Springer C. Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer? Radiother Oncol. 2011;100:463–7.

    Article  PubMed  Google Scholar 

  6. Yoshioka Y, Nose T, Yoshida K, Inoue T, Yamazaki H, Tanaka E, Shiomi H, Imai A, Nakamura S, Shimamoto S, Inoue T. High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial. Int J Radiat Oncol Biol Phys. 2000;48:675–81.

    Article  CAS  PubMed  Google Scholar 

  7. Hiratsuka J, Jo Y, Yoshida K, Nagase N, Fujisawa M, Imajo Y. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004;59:684–90.

    Article  PubMed  Google Scholar 

  8. Akimoto T, Katoh H, Kitamoto Y, Tamaki T, Harada K, Shirai K, Nakano T. Rectal bleeding after high-dose-rate brachytherapy combined with hypofractionated external-beam radiotherapy for localized prostate cancer: impact of rectal dose in high-dose-rate brachytherapy on occurrence of grade 2 or worse rectal bleeding. Int J Radiat Oncol Biol Phys. 2006;65:364–70.

    Article  PubMed  Google Scholar 

  9. Sato M, Mori T, Shirai S, Kishi K, Inagaki T, Hara I. High-dose-rate brachytherapy of a single implant with two fractions combined with external beam radiotherapy for hormone-naive prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72:1002–9.

    Article  PubMed  Google Scholar 

  10. Prada JP, Mendez L, Fernandez J, González H, Jiménez I, Arrojo E. Long-term biochemical results after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy for high risk prostate cancer. Radiat Oncol. 2012;7:31.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Morton CG, Loblaw AD, Chung H, Tsang G, Sankreacha R, Deabreu A, Zhang L, Mamedov A, Cheung P, Batchelar D, Danjoux C, Szumacher E. Health-related quality of life after single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2011;80:1299–305.

    Article  PubMed  Google Scholar 

  12. Wattson AD, Chen MH, Moul WJ, Moran BJ, Dosoretz DE, Robertson CN, Polascik TJ, Braccioforte MN, Salenius SA, D’Amico AV. The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: implications for treatment selection. Int J Radiat Oncol Biol Phys. 2012;82:e773–9.

    Article  PubMed  Google Scholar 

  13. Phan J, Swanson AD, Levy BL, Kudchadker RJ, Bruno TL, Frank SJ. Late rectal complications after prostate brachytherapy for localized prostate cancer. Cancer. 2009;115:1827–39.

    Article  PubMed  Google Scholar 

  14. Hsu IC, Bae K, Shinohara K, Pouliot J, Purdy J, Ibbott G, Speight J, Vigneault E, Ivker R, Sandler H. Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321. Int J Radiat Oncol Biol Phys. 2010;78:751–8.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Egawa S, Shimura S, Irie A, Kitano M, Nishiguchi I, Kuwao S, Hasegawa K, Baba S. Toxicity and health-related quality of life during and after high dose rate brachytherapy followed by external beam radiotherapy for prostate cancer. Jpn J Clin Oncol. 2001;31:541–7.

    Article  CAS  PubMed  Google Scholar 

  16. Okamoto M, Ishikawa H, Ebara T, Kato H, Tamaki T, Akimoto T, Ito K, Miyakubo M, Yamamoto T, Suzuki K, Takahashi T, Nakano T. Rectal bleeding after high-dose-rate brachytherapy combined with hypofractionated external-beam radiotherapy for localized prostate cancer: the relationship between dose-volume histogram parameters and the occurrence rate. Int J Radiat Oncol Biol Phys. 2012;82:e211–7.

    Article  PubMed  Google Scholar 

  17. Araki F, Kouno T, Ohno T, Kakei K, Yoshiyama F, Kawamura S. Measurement of absorbed dose-to-water for an HDR192Ir source with ionization chambers in a sandwich setup. Med. Phys. 2013;40:092101-1–8.

    Article  Google Scholar 

  18. Noda Y, Sato M, Shintaro S, Kishi K, Inagaki T, Mori T, Hara I. Efficacy and safety of high-dose-rate brachytherapy of single implant with two fractions combined with external beam radiotherapy for hormone-naïve localized prostate cancer. Cancers. 2011;3:3585–600.

    Article  PubMed Central  PubMed  Google Scholar 

  19. Ishikawa H, Sato M, Shintaro S, Kishi K, Naya Y, Tokunaga H. Interfractional fluctuation of rectal dose in high dose rate brachytherapy for prostate cancer. Radiat Med. 2006;24:610–6.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Radiology, Wakayama Medical University, 811-1 Kimiidera, Wakayama Shi, Wakayama, 641-8510, Japan

    Noritaka Shimizu, Yasutaka Noda, Morio Sato, Shintaro Shirai, Nobuyuki Kawai, Shinji Harada, Takaki Sakamoto & Tadayoshi Nishioku

Authors
  1. Noritaka Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yasutaka Noda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Morio Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shintaro Shirai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nobuyuki Kawai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shinji Harada
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Takaki Sakamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tadayoshi Nishioku
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Morio Sato.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shimizu, N., Noda, Y., Sato, M. et al. Radiation dose to rectum in high-dose-rate brachytherapy with a single implant and two fractions for prostate cancer, and its prediction by prostate volume. Radiol Phys Technol 8, 18–25 (2015). https://doi.org/10.1007/s12194-014-0281-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12194-014-0281-2

Keywords

Search

Navigation